Sildenafil Citrate Tablet
Product Images NDC 82804-251

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 82804-251). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

82804-251-11 (Sildenafil Citrate 25 mg 30s)

Label for Sildenafil 25 mg tablets, each containing Sildenafil citrate USP equivalent to 25 mg Sildenafil. The label shows a package of 1000 tablets by Proficient Rx LP. Tablets are described as pale blue to blue, round film-coated, debossed with "25" on one side and "SL" on the other. Manufacturer is Umedica Laboratories Pvt. Ltd., India. Storage at 25°C (77°F) is recommended. Includes QR codes, barcode, and multiple small printed duplicate labels.*

FDA Label Image

Sildenafil-citrate-figure-1 (Sildenafil Citrate Figure 1)

A line graph showing the mean change from baseline in sitting systolic blood pressure over 24 hours in healthy volunteers. The X-axis represents time post dose in hours, and the Y-axis shows change in systolic blood pressure in mmHg. Two lines compare effects of Sildenafil 100 mg and placebo over time.*

FDA Label Image

Sildenafil-citrate-figure-2 (Sildenafil Citrate Figure 2)

A line graph showing mean standing systolic blood pressure change from baseline over 8 hours postdose. Two lines compare Doxazosin plus placebo and Doxazosin plus Sildenafil 25 mg, depicting blood pressure changes over time in hours.*

FDA Label Image

Sildenafil-citrate-figure-3 (Sildenafil Citrate Figure 3)

A line graph showing mean changes in standing systolic blood pressure over time (hours) postdose. Two data series are displayed: Doxazosin plus Placebo (blue line with round markers) and Doxazosin plus Sildenafil 50 mg (black line with diamond markers). The graph indicates blood pressure changes from baseline for up to 8 hours postdose.*

FDA Label Image

Sildenafil-citrate-figure-4 (Sildenafil Citrate Figure 4)

A line graph showing mean standing systolic blood pressure change from baseline over time post-dosing. The x-axis represents time in hours (0 to 8 hours) and the y-axis represents blood pressure change in mmHg (-50 to 40 mmHg). Two lines compare the effects of Doxazosin with Sildenafil 100 mg and Doxazosin with Placebo over the time period.*

FDA Label Image

Sildenafil-citrate-figure-5 (Sildenafil Citrate Figure 5)

A line graph showing mean plasma concentrations of Sildenafil over time in healthy male volunteers, comparing an unspecified treatment with a commercial tablet. The y-axis represents plasma concentration (ng/mL) and the x-axis shows time post dose (hours). The graph highlights concentration changes up to 24 hours after dosing.*

FDA Label Image

Sildenafil-citrate-figure-6 (Sildenafil Citrate Figure 6)

Two bar charts comparing percentages of patients at endpoint by baseline score for the effects of sildenafil citrate versus placebo on maintenance of erection. Each chart shows distribution of baseline scores from 0 to 5 on the horizontal axis and percentage of patients on the vertical axis, with multiple shaded bars representing different score categories.*

FDA Label Image

Sildenafil-citrate-figure-7 (Sildenafil Citrate Figure 7)

A bar chart showing the percentage of patients reporting improvement by treatment group: Placebo (24%), Sildenafil citrate 25 mg (63%), Sildenafil citrate 50 mg (74%), and Sildenafil citrate 100 mg (82%). The x-axis lists treatment groups with sample sizes, and the y-axis represents percentage values from 0 to 100.*

FDA Label Image

Sildenafil-citrate-structure (Sildenafil Citrate Structure)

Chemical structure of sildenafil citrate, showing its molecular arrangement including the core ring system and citrate moiety. The diagram depicts the atomic connections and functional groups characteristic of this active pharmaceutical ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.